


pyridostigmine

Chemical Properties

CAS No. :	155-97-5
Formula:	C ₉ H ₁₃ N ₂ O ₂
Molecular Weight:	181.21
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Pyridostigmine(Regonol) is an acetylcholinesterase inhibitor that can treat myasthenia gravis by increasing acetylcholine at the postsynaptic motor endplate.
Targets(IC50)	Cholinesterase (ChE)
In vivo	Pyridostigmine holds promise for the treatment of various gastrointestinal symptoms in SSc patients, particularly in patients with refractory constipation. Though side effects may limit its use, most patients who experienced benefit chose to continue therapy[1].

Solubility Information

Solubility	DMSO: 247.5 mg/mL (1365.82 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 10 mg/mL (55.18 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	5.5185 mL	27.5923 mL	55.1846 mL
5 mM	1.1037 mL	5.5185 mL	11.0369 mL
10 mM	0.5518 mL	2.7592 mL	5.5185 mL
50 mM	0.1104 mL	0.5518 mL	1.1037 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ahuja N K , Mische L , Clarke J O , et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis[J]. Semin Arthritis Rheum, 2018:S0049017217305498.

Byun J I , Moon J , Kim D Y , et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension[J]. Neurology, 2017:10.1212/WNL.0000000000004340.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481